Wells Fargo raised the firm’s price target on Axsome Therapeutics (AXSM) to $160 from $140 and keeps an Overweight rating on the shares. The ...

Sources: FactSet, Tullett Prebon Commodities & Futures: Futures prices are delayed at least 10 minutes as per exchange requirements. Change value during the period between open outcry settle and ...

Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Shopify turned in quarterly revenue and gross merchandise volume above estimates, but it wasn’t enough to lift shares. Shopify stock fell 8.4% to $109.85 in premarket trading Tuesday. For its fourth ...

It's been a strong day for Axsome Therapeutics. Its shares are now trading at $127.02, marking a 20.1% change since the ...

Real-time index price for TSX Consumer Staples Capped Index (TTCS), along with buy or sell indicators, analysis, charts, historical performance, news and more ...

Real-time index price for TSX Canadian Dividend Aristocrats Index (TXDV), along with buy or sell indicators, analysis, charts, historical performance, news and more ...

NASDAQ AXSM opened at $106.46 on Wednesday. Axsome Therapeutics has a one year low of $64.11 and a one year high of $111.51. The company has a debt-to-equity ratio of 1.97, a quick ratio of 2.37 ...

This news article is based on a press release statement from Axsome Therapeutics (NASDAQ:AXSM). The company continues to focus on addressing critical gaps in CNS treatment and advancing patient ...

Lineage Cell Therapeutics LCTX has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below offers a condensed view ...

Axsome Therapeutics has finally jumped all the hurdles in a challenging regulatory saga, winning approval for its oral migraine drug Symbravo. The rapid-acting treatment is approved for the acute ...